Impact of the receptor for advanced glycation end products genetic polymorphisms on the progression in uterine cervical cancer

9Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.

Abstract

To date, few studies have explored the effects of single nucleotide polymorphisms (SNPs) of the receptor for advanced glycation end products (RAGE) in uterine cervical cancer. Therefore, we conducted this study to investigate the involvement of RAGE SNPs in cervical cancer. In total, 117 patients with cervical invasive cancer, 84 with precancerous lesions, and 320 normal women were recruited consecutively. Real-time polymerase chain reaction was used to examine the genotypic frequencies of RAGE SNPs. The results indicated that among the four RAGE SNPs, only the GT/TT genotype of rs184003 was distributed differently between patients with cervical neoplasias and the normal controls, with GG as a reference. Moreover, cervical cancer patients with genotypes TA/AA in rs1800624 exhibited a lower risk of parametrium invasion, moderate-to-poor cell differentiation, and pelvic lymph node metastasis. In conclusion, RAGE SNPs rs1800624 was associated with some clinicopathological variables in cervical cancer.

Cite

CITATION STYLE

APA

Lee, C. Y., Ng, S. C., Hsiao, Y. H., Yang, S. F., Hsu, C. F., & Wang, P. H. (2018). Impact of the receptor for advanced glycation end products genetic polymorphisms on the progression in uterine cervical cancer. Journal of Cancer, 9(21), 3886–3893. https://doi.org/10.7150/jca.27960

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free